Llwytho...
Existing highly accumulating lysosomotropic drugs with potential for repurposing to target COVID-19
Given the speed of viral infection spread, repurposing of existing drugs has been given the highest priority in combating the ongoing COVID-19 pandemic. Only drugs that are already registered or close to registration, and therefore have passed lengthy safety assessments, have a chance to be tested i...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Biomed Pharmacother |
|---|---|
| Prif Awduron: | , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
The Author(s). Published by Elsevier Masson SAS.
2020
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7392152/ https://ncbi.nlm.nih.gov/pubmed/32763818 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.biopha.2020.110582 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|